| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 59 |
| 1 | CARBOPLATIN | 38 |
| 2 | IPILIMUMAB | 32 |
| 3 | PACLITAXEL | 24 |
| 4 | DURVALUMAB | 21 |
| 5 | PEMETREXED DISODIUM | 19 |
| 6 | PEMETREXED | 17 |
| 7 | CISPLATIN | 15 |
| 8 | METHYLPREDNISOLONE | 12 |
| 9 | GEMCITABINE HYDROCHLORIDE | 9 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NIVOLUMAB AND RELATLIMAB-RMBW | 2 | 0.0039 |
| 1 | CEMIPLIMAB-RWLC | 6 | 0.0029 |
| 2 | TREMELIMUMAB | 8 | 0.0018 |
| 3 | PYRIDOSTIGMINE BROMIDE ORAL | 6 | 0.0017 |
| 4 | DURVALUMAB | 21 | 0.0010 |
| 5 | ETHIODIZED OIL | 1 | 0.0008 |
| 6 | IPILIMUMAB | 32 | 0.0007 |
| 7 | NIVOLUMAB | 59 | 0.0006 |
| 8 | ENFORTUMAB VEDOTIN | 4 | 0.0005 |
| 9 | PEMETREXED DISODIUM | 19 | 0.0005 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Lymphocyte Activation Gene-3 Blocker [EPC] | 2 | 0.0039 |
| 1 | Programmed Death Ligand-1 Blocker [EPC] | 21 | 0.0010 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 40 | 0.0008 |
| 3 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 61 | 0.0006 |
| 4 | Selective T Cell Costimulation Blocker [EPC] | 1 | 0.0002 |
| 5 | alpha-Glucosidase Inhibitor [EPC] | 1 | 0.0002 |
| 6 | Platinum-based Drug [EPC] | 56 | 0.0002 |
| 7 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 1 | 0.0002 |
| 8 | Microtubule Inhibitor [EPC] | 25 | 0.0002 |
| 9 | Human Immunoglobulin G [EPC] | 2 | 0.0001 |